HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MAC

This article was originally published in The Rose Sheet

Executive Summary

John Demsey tapped as managing director for Make-Up Art Cosmetics, effective July 1, Estee Lauder announced April 2. Currently senior VP, sales & education, Estee Lauder U.S.A. & Canada and Donna Karan Cosmetics Company, Demsey will be responsible for all product development, marketing, sales and distribution of the MAC brand. He will have direct responsibilities for North American markets and work with Estee Lauder International marketing and affiliate structures in other markets, the company said. MAC founder and Chairman Frank Toskan will continue to act as creative director. Demsey joined Estee Lauder in 1991 as VP-Estee Lauder U.S.A., field sales manager, West Coast. His appointment to the newly created position follows Lauder's completion of its MAC purchase at the end of February ("The Rose Sheet" March 2, p. 8)...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS005293

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel